PhysIOL

In 1986, stemming from work at the University of Liège in Belgium, PhysIOL was founded with a clear mission in the world of ophthalmology. The company dedicated itself to the research, development, and manufacturing of intraocular lenses (IOLs), the tiny artificial lenses implanted in the eye to treat cataracts. The company, led by CEO Marc Nolet, focused on creating high-quality, innovative lenses. This strategy led to a diverse product line, ranging from standard monofocal lenses to advanced trifocal options, addressing a growing demand for better vision after cataract surgery. Their commitment to quality allowed them to expand their reach, with surgeons in over 60 countries using their products. A significant chapter in the company's story unfolded in late 2018 when Beaver-Visitec International (BVI), backed by TPG Capital, announced its definitive agreement to acquire PhysIOL from its then-owner, TA Associates. This move was a strategic play for BVI to enter the high-growth premium IOL market and transform itself into a more comprehensive ophthalmic platform. The transaction, completed in the first quarter of 2019, integrated PhysIOL’s specialized lens portfolio into BVI's broader offering of surgical devices. Marc Nolet continued in a leadership role and joined the BVI board, ensuring a smooth transition and continued focus on innovation.